Cemex SAB (CX)
NYSE:CX
Holding CX?
Track your performance easily

Cemex SAB (CX) Income Statement

895 Followers

Cemex SAB Income Statement

Last quarter (Q4 2023), Cemex SAB's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q4, Cemex SAB's net income was $―. See Cemex SAB’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 3.96B$ 17.39B$ 15.58B$ 14.55B$ 12.81B$ 13.13B
Cost of Revenue
$ 2.75B$ 11.53B$ 10.76B$ 9.74B$ 8.59B$ 11.80B
Gross Profit
$ 1.21B$ 5.86B$ 4.82B$ 4.64B$ 4.08B$ 1.33B
Operating Expense
$ 841.89M$ 4.05B$ 3.26B$ -2.94B$ -29.00M$ -32.00M
Operating Income
$ 363.42M$ 1.81B$ 1.56B$ 1.73B$ 1.31B$ 1.33B
Net Non Operating Interest Income Expense
$ -37.92M$ -600.00M$ 422.00M$ -698.39M$ -895.00M$ -782.00M
Other Income Expense
$ -270.00K$ -98.00M$ -369.00M$ 104.04M$ -49.00M$ -49.00M
Pretax Income
$ 325.23M$ 1.45B$ 770.00M$ 931.70M$ -1.30B$ 253.00M
Tax Provision
$ 50.52M$ 1.25B$ 209.00M$ 137.00M$ 36.00M$ 162.00M
Earnings From Equity Interest Net Of Tax
-$ 98.00M$ 30.90M$ 54.00M$ 49.00M$ 49.00M
Net Income Common Stockholders
$ 494.09M$ 182.00M$ 858.00M$ 753.00M$ -1.47B$ 143.00M
Basic EPS
$ 10.20-$ 0.03$ 0.04$ -0.06-
Diluted EPS
$ 10.20-$ 0.03$ 0.04$ -0.06-
Basic Average Shares
$ 1.45B-$ 43.55B$ 44.12B$ 44.13B$ 45.39B
Diluted Average Shares
$ 1.45B-$ 43.55B$ 44.12B$ 44.13B$ 45.39B
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 3.59B$ 15.58B$ 14.02B$ 12.66B$ 11.47B$ 11.77B
Net Income From Continuing And Discontinued Operation
$ 494.09M$ 182.00M$ 858.00M$ 753.00M$ -1.47B$ 143.00M
Normalized Income
$ 257.26M$ 1.07B----
Interest Expense
$ 43.33M-----
EBIT
$ 368.56M$ 1.98B$ 1.20B$ 1.64B$ -510.00M$ 253.00M
EBITDA
$ 417.07M$ 3.21B$ 2.32B$ 2.76B$ 595.00M$ -792.00M
Currency in USD

Cemex SAB Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis